(47) Patients (N=413) had inadequate glycemic control despite basal insulin 20 to 40 units/d in combination with metformin with or without a sulfonylurea or meglitinide
. At randomization to IDegLira or degludec, patients were continued on metformin alone.
analogues in the treatment of type 2 diabetes mellitus," Drugs & Aging, vol.
Regarding their medication regimens, the number of patients on hypoglycemia-inducing oral hypoglycemic agents (OHAs), namely, sulfonylureas and meglitinide
analogues, insulin, or both, was 36, 215, and 18, respectively.
To date there are several classes of oral antidiabetic medications including biguanides, sulfonylureas, meglitinide
, thiazolidinedione, dipeptidyl peptidase 4 inhibitors, sodium-glucose cotransporter inhibitors, and [alpha]-glucosidase inhibitors [4, 5].
Tolbutamide and gliclazide block channels containing SUR1 ([beta]-cell type) but not SUR2 (cardiac, smooth muscle types), whereas glibenclamide, glimepiride, repaglinide, and meglitinide
block both types of the channels .
The longitudinal retrospective analysis of a large administrative claims database found a 10% incidence of fracture on sulfonylureas and 11% on thiazolidinediones, compared with 7% on biguanides (metformin), 8% on dipeptidyl peptidase-4 (DPP-4) inhibitors, 11% on meglitinide
analogues, and 6% on incretin mimetic agents.
The fast should also be broken if blood glucose reaches Less than 70 mg/dl (3.9 mmol/l) in the first few hours after the start of fast, especially if insulin, sulphonylurea drugs or meglitinide
are taken at Sehar.
analogues: a review of clinical data focused on recent trials.
Repaglinide and nateglinide, which are meglitinide
analogs, decrease ATP-sensitive [K.sup.+] conductance in a glucose-dependent manner.
Prandin, classified as a meglitinide
, lowers blood glucose levels by stimulating the release of insulin from the pancreas and is dependent upon functioning beta cells in the pancreatic islets.
 reported a significantly decreased risk of hypoglycemia associated with the use of DPP-4 inhibitors and an increased risk of hypoglycemic events among users of insulin, sulfonylureas, and/or other oral diabetes medications (meglitinide
and a-glucosidase inhibitors).
Although there seems to be no significant effect of antidiabetic treatments on Hcy levels as a whole (SMD -0.53 (95% CI -1.60 to 0.53)), combination treatment with thiazolidinediones and diguanides or meglitinide
and thiazolidinediones has shown significant effects on lowering serum Hcy (SMD -1.67 (95% CI -2.85 to -0.50) and SMD -4.40 (95% CI -4.94 to -3.86), resp.).